

PINTAD

The Pharma Imaging Network for Therapeutics and Diagnostics

Meeting Minutes

Topic	Theranostics
Date	11 December 2020
Speaker(s)	Carolyn J. Anderson

Topic/Slide	Discussion
Presentation Content	<i>See Theranostics Slides</i>
Q&A	<p><i>How much predictive value can one give to the animal model?</i></p> <p>Pretty predictive. In terms of Cu64-DOTATATE, a first in human trial was started. The DOTA compounds are out there so people want to use them. Simpler to get a compound approved that has already been vetted.</p> <p><i>What preclinical to clinical translational advice/lessons learned would you share with the group?</i></p> <p>Various companies have their own pre-clinical groups and do their own research. The imaging is really important in the pre-clinical studies. Need to start with the simple straightforward bio-distribution studies. You can do nice longitudinal studies with imaging. In the late 1990s there wasn't imaging for this research. Imaging allows you to look at treatments/outcomes non-invasively.</p> <p><i>What is the future of alpha therapy?</i></p> <p>Actinium 225 clinical trial with PSMA. Need to get around the toxicity problem with the salivary glands and tear ducts – it may be permanent with the alpha therapy (non-recoverable toxicity). Have to do the animal studies on this. The field is moving towards more alpha research. Beta emitters won't go away. Alphas have a very short range. When there are large/bulky tumors, beta emitters are necessary. Likely to so combination therapy.</p>